← Back to Clinical Trials
Recruiting NCT07728643

NCT07728643 Endothelial Extracellular Vesicles as Biomarkers of Endothelial Activation in Children With Newly Diagnosed Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07728643
Status Recruiting
Phase
Sponsor Josip Juraj Strossmayer University of Osijek
Condition Pediatric Hypertension
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2026-04-01
Primary Completion 2029-04-30

Eligibility & Interventions

Sex All sexes
Min Age 6 Years
Max Age 17 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2026-04-01 with a primary completion date of 2029-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Childhood hypertension is associated with early endothelial dysfunction and an increased risk of future cardiovascular disease. Endothelial extracellular vesicles (EEVs) have emerged as promising biomarkers of endothelial activation; however, their role in pediatric hypertension remains poorly understood. This observational case-control study aims to compare circulating EEV concentrations between normotensive children and children with newly diagnosed, untreated primary hypertension. The study will also investigate the associations between EEV levels, blood pressure, microvascular endothelial function assessed by laser Doppler flowmetry, and circulating biomarkers of endothelial activation. The findings may improve understanding of endothelial injury in pediatric hypertension and support the development of non-invasive biomarkers for early cardiovascular risk assessment.

Eligibility Criteria

Inclusion Criteria: * Children and adolescents aged 6-17 years. * Written informed consent from a parent or legal guardian and assent from the participant when appropriate. * Normotensive status or newly diagnosed, previously untreated primary hypertension according to current pediatric hypertension guidelines. * Ability to comply with study procedures. Exclusion Criteria: * Secondary hypertension. * Previous antihypertensive treatment. * Congenital heart disease or other significant cardiovascular disease. * Diabetes mellitus. * Chronic kidney disease. * Autoimmune or chronic inflammatory disease. * Acute infection at the time of enrollment. * Malignancy. * Use of medications known to affect endothelial function. * Inability to comply with study procedures.

Contact & Investigator

Central Contact

Ivana Jukić, MD, PhD

✉ medicina@mefos.hr

📞 +38531512800

Principal Investigator

Ivana Jukić, MD, PhD

STUDY CHAIR

Faculty of Medicine Osijek, Josip Juraj Strossmayer of Osijek

Frequently Asked Questions

Who can join the NCT07728643 clinical trial?

This trial is open to participants of all sexes, aged 6 Years or older, up to 17 Years, studying Pediatric Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07728643 currently recruiting?

Yes, NCT07728643 is actively recruiting participants. Contact the research team at medicina@mefos.hr for enrollment information.

Where is the NCT07728643 trial being conducted?

This trial is being conducted at Osijek, Croatia.

Who is sponsoring the NCT07728643 clinical trial?

NCT07728643 is sponsored by Josip Juraj Strossmayer University of Osijek. The principal investigator is Ivana Jukić, MD, PhD at Faculty of Medicine Osijek, Josip Juraj Strossmayer of Osijek. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology